切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2020, Vol. 09 ›› Issue (06) : 596 -601. doi: 10.3877/cma.j.issn.2095-3232.2020.06.021

所属专题: 文献

基础研究

lncRNA-DUXAP9/DUXAP10表达与肝癌肝切除患者预后的关系
朱倩1, 侍超2, 沈晶尧2, 徐亮2, 应杰2, 胡立平2,()   
  1. 1. 430071 武汉大学中南医院肝胆胰外科
    2. 211700 江苏省淮安市盱眙县人民医院普通外科
  • 收稿日期:2020-08-13 出版日期:2020-12-10
  • 通信作者: 胡立平
  • 基金资助:
    国家自然科学青年科学基金(82002589); 武汉大学中南医院优博基金项目(ZNYB2019007); 武汉大学青年教师资助项目(2042020kf0145)

Relationship between lncRNA-DUXAP9/DUXAP10 expression and clinical prognosis of hepatocellular carcinoma patients after hepatectomy

Qian Zhu1, Chao Shi2, Jingyao Shen2, Liang Xu2, Jie Ying2, Liping Hu2,()   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
    2. Department of General Surgery, Xuyi People's Hospital, Huai'an 211700, China
  • Received:2020-08-13 Published:2020-12-10
  • Corresponding author: Liping Hu
引用本文:

朱倩, 侍超, 沈晶尧, 徐亮, 应杰, 胡立平. lncRNA-DUXAP9/DUXAP10表达与肝癌肝切除患者预后的关系[J]. 中华肝脏外科手术学电子杂志, 2020, 09(06): 596-601.

Qian Zhu, Chao Shi, Jingyao Shen, Liang Xu, Jie Ying, Liping Hu. Relationship between lncRNA-DUXAP9/DUXAP10 expression and clinical prognosis of hepatocellular carcinoma patients after hepatectomy[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(06): 596-601.

目的

探讨长链非编码RNA(lncRNA)-DUXAP9/DUXAP10表达与肝细胞癌(肝癌)肝切除患者预后的关系。

方法

标本来源于2012年1月至2015年12月在盱眙县人民医院行肝切除的63例肝癌患者。患者均签署知情同意书,符合医学伦理学规定。其中男35例,女28例;年龄20~70岁,中位年龄52岁。采用lncRNAs基因谱芯片筛选异常表达基因,实时荧光定量PCR检测基因表达水平。采用Kaplan-Meier法绘制生存曲线,生存分析比较采用Log-rank检验。肝癌肝切除患者预后影响因素分析采用Cox比例风险回归模型。

结果

lncRNAs基因谱芯片结果显示,256条lncRNAs异常表达,162条表达上调,94条下调。进一步筛选出2个异常表达基因lncRNA-DUXAP9和lncRNA-DUXAP10(fold change=6.35,4.53;P<0.05)。生存分析显示,lncRNA-DUXAP9/DUXAP10表达与肝癌肝切除患者总体生存和无瘤生存相关(χ2=1.817,1.693和2.163,1.961;P<0.05)。Cox多因素分析显示,lncRNA-DUXAP9/DUXAP10表达为肝癌肝切除患者预后的独立危险因素(HR=2.524,1.316;P<0.05)。

结论

lncRNA-DUXAP9/DUXAP10在肝癌中高表达,其高表达为肝癌肝切除患者预后的独立危险因素。

Objective

To explore the relationship between the expression level of long non-coding RNA (lncRNA)-DUXAP9/DUXAP10 and clinical prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy.

Methods

The specimens were collected from 63 HCC patients who underwent hepatectomy in Xuyi People's Hospital from January 2012 to December 2015. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 35 patients were male and 28 female, aged 20-70 years, with a median age of 52 years. The abnormally-expressed genes were screened by lncRNAs microarray. The mRNA expression levels were detected by real-time fluorescence quantitative PCR. Survival curve was delineated by Kaplan-Meier survival curve. Survival analysis was conducted by Log-rank test. The prognostic factors of HCC patients after hepatectomy were identified by Cox's proportional hazard regression model.

Results

The lncRNAs microarray showed that 256 lncRNAs expressed abnormally, expression of 162 lncRNAs were up-regulated and 94 were down-regulated. Two abnormally-expressed genes, lncRNA-DUXAP9 and lncRNA-DUXAP10, were further screened (fold change=6.35, 4.53; P<0.05). Survival analysis demonstrated that the expression of lncRNA-DUXAP9/DUXAP10 was significantly correlated with the overall survival and tumor-free survival of HCC patients after hepatectomy (χ2=1.817, 1.693 and 2.163, 1.961; P<0.05). Cox's proportional hazard regression model indicated that the expression levels of lncRNA-DUXAP9/DUXAP10 were the independent risk factors for clinical prognosis of HCC patients after hepatectomy (HR=2.524, 1.316; P<0.05).

Conclusions

lncRNA-DUXAP9/DUXAP10 are highly expressed in HCC patients, which are the independent risk factors for clinical prognosis of HCC patients undergoing hepatectomy.

图1 基因表达谱芯片聚类分析筛选lncRNAs
图2 肝癌细胞系中lncRNA-DUXAP9/DUXAP10相对表达水平
图3 lncRNA-DUXAP9/DUXAP10表达与肝癌肝切除患者总体生存和无瘤生存关系的Kaplan-Meier生存曲线
表1 肝癌肝切除患者预后的影响因素分析
[1]
Han Li C, Chen Y. Small and long non-coding RNAs: novel targets in perspective cancer therapy[J]. Curr Genomics, 2015, 16(5):319-326.
[2]
Morceau F, Chateauvieux S, Gaigneaux A, et al. Long and short non-coding RNAs as regulators of hematopoietic differentiation[J]. Int J Mol Sci, 2013, 14(7):14744-14770.
[3]
Uchida S, Bolli R. Short and long noncoding RNAs regulate the epigenetic status of cells[J]. Antioxid Redox Signal, 2018, 29(9):832-845.
[4]
Chen M, Zhuang C, Liu Y, et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer[J]. Cancer Lett, 2016, 376(1):155-164.
[5]
Yao Y, Ma J, Xue Y, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152[J]. Cancer Lett, 2015, 359(38): 75-86.
[6]
Wang D, Ding L, Wang L, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer[J]. Oncotarget, 2015, 6(38):41045-41055.
[7]
Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer:current status and future perspectives[J]. Mol Cancer, 2016, 15(1):39.
[8]
Li C, Chen J, Zhang K, et al. Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma[J]. Cell Physiol Biochem, 2015, 36(2):423-434.
[9]
Wang F, Ying HQ, He BS, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway[J]. Oncotarget, 2015, 6(10):7899-7917.
[10]
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[11]
Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009[J]. Lancet Oncol, 2009, 10(11):1111-1118.
[12]
Hefaiedh R, Sabbeh M, Ennaifer R, et al. Percutaneous treatment versus hepatic resection for the treatment of small hepatocellular carcinoma[J]. Tunis Med, 2015, 93(3):132-137.
[13]
Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(37):13453-13465.
[14]
Hao S, Fan P, Chen S, et al. Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery in patients with hepatocellular carcinoma[J]. J Gastrointest Surg, 2017, 21(12):312-320.
[15]
Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review[J]. Hepatol Int, 2008, 2(1):17-30.
[16]
Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma[J]. Ann Surg, 2009, 249(5):799-805.
[17]
Liu Z, Li X, Sun N, et al. Microarray profiling and co-expression network analysis of circulating lncRNAs and mRNAs associated with major depressive disorder[J]. PLoS One, 2014, 9(3):e93388.
[18]
Leidenroth A, Hewitt JE. A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene[J]. BMC Evol Biol, 2010(10):364.
[19]
Eidahl JO, Giesige CR, Domire JS, et al. Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4[J]. Hum Mol Genet, 2016, 25(20):4577-4589.
[20]
Töhönen V, Katayama S, Vesterlund L, et al. Novel PRD-like homeodomain transcription factors and retrotransposon elements in early human development[J]. Nat Commun, 2015(6):8207.
[21]
Booth HA, Holland PW. Annotation, nomenclature and evolution of four novel homeobox genes expressed in the human germ line[J]. Gene, 2007, 387(1/2):7-14.
[22]
Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs[J]. Nature, 2013, 500(7464):598-602.
[23]
Zhou X, Ye F, Yin C, et al. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer[J]. Cell Physiol Biochem, 2015, 36(4):1440-1452.
[24]
Wang Y, Gao S, Liu G, et al. Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma[J]. Cell Physiol Biochem, 2014, 33(4):1225-1238.
[25]
Tang Q, Ni Z, Cheng Z, et al. Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC[J]. Cell Physiol Biochem, 2015, 37(3):1002-1009.
[1] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[2] 叶晓琳, 刘云飞, 庞明泉, 王海久, 任利, 侯立朝, 于文昊, 王志鑫, 樊海宁. 肝再生细胞来源及调控机制的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 96-99.
[3] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[4] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 曹迪, 张玉茹. 经腹腔镜生物补片修补直肠癌根治术后盆底疝1例[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 115-116.
[7] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[8] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[9] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[10] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[11] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[12] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[13] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[14] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[15] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
阅读次数
全文


摘要